Cargando…

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

HER3 belongs to the human epidermal growth factor receptor (HER) family which also includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the HER family, HER3 lacks or has little intrinsic tyrosine kinase activity. It frequently co-expresses and forms heterodimers with other rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyu, Hui, Han, Amy, Polsdofer, Erik, Liu, Shuang, Liu, Bolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090011/ https://www.ncbi.nlm.nih.gov/pubmed/30109175 http://dx.doi.org/10.1016/j.apsb.2018.05.010

Ejemplares similares

Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
por: Liu, Xiaolong, et al.
Publicado: (2019)

Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
por: Lyu, Hui, et al.
Publicado: (2018)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023)

Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
por: Liu, Shuang, et al.
Publicado: (2021)

Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer
por: Lyu, Hui, et al.
Publicado: (2018)

HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells
por: Lyu, Hui, et al.
Publicado: (2023)

Targeting of erbB3 receptor to overcome resistance in cancer treatment
por: Ma, Jian, et al.
Publicado: (2014)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Protein acylation: mechanisms, biological functions and therapeutic targets
por: Shang, Shuang, et al.
Publicado: (2022)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
por: Conradi, Lena-Christin, et al.
Publicado: (2019)

Targeting G(i/o) protein–coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy
por: Lyu, Cancan, et al.
Publicado: (2021)

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Editorial: Special Issue—Understanding and Targeting Heart Failure: From Biology to Therapeutics
por: Pu, Jun, et al.
Publicado: (2023)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics
por: Sims, Jessica D., et al.
Publicado: (2017)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting
por: Tan, Yaw Sing, et al.
Publicado: (2019)

Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target
por: Zhang, Jin, et al.
Publicado: (2020)

HER2 as a novel therapeutic target for cervical cancer
por: Oh, Doo-Yi, et al.
Publicado: (2015)

Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
por: Luo, Liyun, et al.
Publicado: (2021)

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013)

Pharmacological Targeting of the Pseudokinase Her3
por: Xie, Ting, et al.
Publicado: (2014)

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
por: Cheung, Lawrence H., et al.
Publicado: (2019)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
por: Miladinova, Daniela
Publicado: (2023)

HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
por: Khan, A N, et al.
Publicado: (2006)

HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
por: Ma, Juan, et al.
Publicado: (2013)

Construction and evaluation of a novel humanized HER2-specific chimeric receptor
por: Sun, Meili, et al.
Publicado: (2014)

Systems Biology Approaches to Understanding the Human Immune System
por: Dhillon, Bhavjinder K., et al.
Publicado: (2020)

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
por: Liu, Ruiqi, et al.
Publicado: (2023)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Understanding Podocyte Biology to Develop Novel Kidney Therapeutics
por: Lal, Mark A., et al.
Publicado: (2018)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
por: Cai, Xiaoqing, et al.
Publicado: (2022)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a2ar2j34kq7t83f42l849q56pd